PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

https://doi.org/10.1016/j.jval.2018.09.2022Get rights and content
Under an Elsevier user license
open archive

Cited by (0)